Cargando…

Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study

BACKGROUND: Enhanced innate immune response is detected in autopsy studies of Parkinson’s disease (PD) but the role of microglia in early pathophysiology is unclear. While the translocator protein 18 kDa (TSPO) that marks glial activation may be high in PD, TSPO expression is not limited to microgli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mills, Kelly A., Du, Yong, Coughlin, Jennifer M., Horti, Andrew G., Jenkins, Katelyn, Spiro, Ergi, Motley, Chelsie S., Dannals, Robert F., Pomper, Martin G., Dawson, Ted M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312881/ https://www.ncbi.nlm.nih.gov/pubmed/37398476 http://dx.doi.org/10.1101/2023.05.28.23290647

Ejemplares similares

First-in-human use of (11)C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor
por: Coughlin, Jennifer M., et al.
Publicado: (2022)

Structure-guided design of CPPC-paired disulfide-rich peptide libraries for ligand and drug discovery
por: Wu, Yapei, et al.
Publicado: (2022)

PET imaging of soluble epoxide hydrolase in non-human primate brain with [(18)F]FNDP
por: Du, Yong, et al.
Publicado: (2020)

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease
por: Park, Jong-Sung, et al.
Publicado: (2021)

In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma
por: Coughlin, J M, et al.
Publicado: (2016)

Multilingual evaluation of interpretable biomarkers to represent language and speech patterns in Parkinson's disease
por: Favaro, Anna, et al.
Publicado: (2023)

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
por: Wang, Zhifu, et al.
Publicado: (2023)

The role of microglial autophagy in Parkinson’s disease
por: Zhu, Rui, et al.
Publicado: (2022)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation
por: Savonenko, Alena V., et al.
Publicado: (2015)

Increased CSF biomarkers of angiogenesis in Parkinson disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Update on CSF Biomarkers in Parkinson’s Disease
por: Kwon, Eun Hae, et al.
Publicado: (2022)

Commercial and business aspects of alpha radioligand therapeutics
por: Ostuni, Emanuele, et al.
Publicado: (2023)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy
por: Kempthorne, Liam, et al.
Publicado: (2020)

Recent Advances in Basic Research for CSF1R-Microglial Encephalopathy
por: Wang, Yan-Li, et al.
Publicado: (2021)

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
por: Spangenberg, Elizabeth, et al.
Publicado: (2019)

Oxidative Stress and Microglial Cells in Parkinson's Disease
por: Peterson, Lynda J., et al.
Publicado: (2012)

Two Novel Intronic Mutations in the CSF1R Gene in Two Families With CSF1R-Microglial Encephalopathy
por: Jiang, Jiwei, et al.
Publicado: (2022)

Editorial: Response assessment of radioligand therapies
por: Lopci, Egesta, et al.
Publicado: (2022)

Association between CSF1 and CSF1R Polymorphisms and Parkinson’s Disease in Taiwan
por: Chang, Kuo-Hsuan, et al.
Publicado: (2019)

Correction to: Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy
por: Kempthorne, Liam, et al.
Publicado: (2020)

Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease
por: Kelly, Rachel, et al.
Publicado: (2020)

Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease
por: Koshimori, Yuko, et al.
Publicado: (2015)

Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson’s Disease Models
por: Tada, Satoshi, et al.
Publicado: (2022)

Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer’s Disease: A CSF/(18)F-FDG-PET Study
por: Bonomi, Chiara Giuseppina, et al.
Publicado: (2023)

The cell biology of Parkinson’s disease
por: Panicker, Nikhil, et al.
Publicado: (2021)

Microglial responses to CSF1 overexpression do not promote the expansion of other glial lineages
por: De, Ishani, et al.
Publicado: (2021)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson’s disease
por: Wu, Chun-Yi, et al.
Publicado: (2019)

Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent
por: Bagchi, Devika P., et al.
Publicado: (2013)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
por: Mendsaikhan, Anarmaa, et al.
Publicado: (2019)

Microglial Ion Channels as Potential Targets for Neuroprotection in Parkinson's Disease
por: Richardson, Jason R., et al.
Publicado: (2013)

Microglial activation in Parkinson’s disease using [(18)F]-FEPPA
por: Ghadery, Christine, et al.
Publicado: (2017)

Fluid and Biopsy Based Biomarkers in Parkinson’s Disease
por: Coughlin, David G., et al.
Publicado: (2023)

CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a0h26gk58l9b3t11uqeds65hdi